Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA ...

Universal mismatch repair (MMR) deficiency testing is widely recommended in patients with colorectal cancer (CRC) and others with a family history of MMR deficiency to identify Lynch syndrome, a ...

Treatment of colorectal cancer (CRC)—the third leading cause of cancer-related death in the United States—remains challenging even today. But according to leading oncologists in the field, ...

Lynch syndrome (LS)–associated colorectal cancer (CRC) is characterized by mismatch repair-deficiency (MMR-D) and/or microsatellite instability (MSI). However, with increasing utilization of germline ...

Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by hypermutation leading to abundant neoantigens that activate an antitumor immune response in the tumor ...

Keytruda received FDA breakthrough therapy designation for MSI-H mCRC, based on promising phase 2 study results in MMR-deficient patients. The study showed a 62% objective response rate in ...

Mismatch repair-deficient (dMMR) colorectal cancer (CRC) is associated with a conspicuous local immune infiltrate; however, its relationship with systemic inflammatory responses remains to be ...

Colorectal cancers (CRCs) with deficiency in the mismatch repair (MMR) genes, such as MLH1, MSH2 or MSH6, are classified as Lynch syndrome, and patients with such cancer are at higher risk for other ...

The supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) is still under review by the Food and Drug Administration (FDA) to treat MSI-H cancer. The supplemental biologics ...